Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

Other illness

• Diagnosis of an autoimmune or inflammatory joint disease other than RA, which would put the participant at risk by participating in the study or would interfere with study assessments/data interpretation, per judgment of the investigator
• Known hypersensitivity to the study drug or its excipients
• Any medical condition which would put the participant at risk by participating in the study or would interfere with study assessments/data interpretation, per judgment of the investigator
  • NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

• Males or females who may benefit from filgotinib as judged by the investigator AND who completed a Gilead sponsored filgotinib parent study for RA as outlined below:
  • Have completed GS-US-417-0301, GS-US-417-0302 or GS-US-417-0303 on study drug
  • OR
  • Have completed GS-US-417-0302 on standard of care therapy due to RA non-responder status
• Females of childbearing potential must have a negative pregnancy test prior to first dose of study drug in the long term extension (LTE)
• Females of childbearing potential who engage in heterosexual intercourse must agree to protocol-approved methods of contraception